Veradigm (MDRX) 10-Q 7 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'MDRX	'
Entity Registrant Name	'ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.	'
Entity Central Index Key	'0001124804	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	180,261,934

CONSOLIDATED_BALANCE_SHEETS_Un

CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$37,345	$62,954
Accounts receivable, net of allowance of $39,355 and $54,252 at September 30, 2014 and December 31, 2013, respectively	340,696	313,486
Deferred taxes, net	55,458	55,468
Prepaid expenses and other current assets	115,212	107,911
Total current assets	548,711	539,819
Long-term marketable securities	1,321	1,329
Fixed assets, net	152,213	174,013
Software development costs, net	85,018	88,244
Intangible assets, net	422,192	455,971
Goodwill	1,200,651	1,189,585
Deferred taxes, net	7,361	7,361
Other assets	153,394	163,341
Total assets	2,570,861	2,619,663
Current liabilities:	'	'
Accounts payable	86,432	72,956
Accrued expenses	79,751	96,499
Accrued compensation and benefits	55,638	80,196
Deferred revenue	277,243	251,038
Current maturities of long-term debt and capital lease obligations	24,703	16,350
Total current liabilities	523,767	517,039
Long-term debt	562,519	545,133
Deferred revenue	26,823	29,080
Deferred taxes, net	86,332	79,694
Other liabilities	88,594	130,572
Total liabilities	1,288,035	1,301,518
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding at September 30, 2014 and December 31, 2013	0	0
Common stock: $0.01 par value, 350,000 shares authorized at September 30, 2014 and December 31, 2013; 264,914 and 180,242 shares issued and outstanding at September 30, 2014, respectively; 263,474 and 178,802 shares issued and outstanding at December 31, 2013, respectively	2,648	2,635
Treasury stock: at cost, 84,672 at September 30, 2014 and December 31, 2013	-278,036	-278,036
Additional paid-in capital	1,745,416	1,716,847
Accumulated deficit	-185,831	-121,556
Accumulated other comprehensive loss	-1,371	-1,745
Total stockholders' equity	1,282,826	1,318,145
Total liabilities and stockholders' equity	$2,570,861	$2,619,663

CONSOLIDATED_BALANCE_SHEETS_Un1

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Accounts receivable, allowance	$39,355	$54,252
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	1,000	1,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	350,000	350,000
Common stock, shares issued	264,914	263,474
Common stock, shares outstanding	180,242	178,802
Treasury stock at cost, shares	84,672	84,672

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:	'	'	'	'
System sales	$21,440	$26,498	$70,601	$85,978
Professional services	54,825	49,003	167,563	169,293
Maintenance	117,454	117,928	348,111	351,840
Transaction processing and other	151,670	136,762	450,695	414,973
Total revenue	345,389	330,191	1,036,970	1,022,084
Cost of revenue:	'	'	'	'
System sales (excluding amortization of software development and acquisition-related assets shown below)	7,313	14,767	25,921	41,176
Professional services	50,224	47,295	146,767	162,278
Maintenance	36,638	35,841	111,123	107,864
Transaction processing and other	99,176	83,735	282,004	251,973
Total cost of revenue	213,933	204,644	627,340	625,827
Gross profit	131,456	125,547	409,630	396,257
Selling, general and administrative expenses	97,034	104,506	273,643	310,326
Research and development	45,962	49,400	151,283	151,881
Asset impairment charges	188	7,371	2,134	10,504
Loss from operations	-18,840	-43,452	-39,844	-100,056
Interest expense	-7,542	-6,895	-22,005	-21,031
Other income (expense), net	171	-826	369	7,523
Loss before income taxes	-26,211	-51,173	-61,480	-113,564
Income tax benefit (provision)	448	2,233	-2,795	30,156
Net loss	-25,763	-48,940	-64,275	-83,408
Loss per share-basic and diluted	($0.15)	($0.27)	($0.36)	($0.47)
Direct Cost Of Revenues [Member]	'	'	'	'
Cost of revenue:	'	'	'	'
Amortization of software development and acquisition-related assets	20,582	23,006	61,525	62,536
Other Costs [Member]	'	'	'	'
Cost of revenue:	'	'	'	'
Amortization of intangible and acquisition-related assets	$7,112	$7,722	$22,414	$23,602

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net loss	($25,763)	($48,940)	($64,275)	($83,408)
Other comprehensive (loss) income, net of taxes:	'	'	'	'
Unrealized gain on marketable securities, net of tax	8	27	19	11
Derivatives qualifying as hedges:	'	'	'	'
Unrealized loss on interest rate swap	0	-79	-38	-112
Reclassification adjustment for loss included in net loss	110	286	465	968
Tax effect	-43	-82	-168	-334
Unrealized gain on interest rate swap, net of tax	67	125	259	522
Change in foreign currency translation adjustments	-824	725	96	-1,724
Total other comprehensive (loss) income	-749	877	374	-1,191
Comprehensive loss	($26,512)	($48,063)	($63,901)	($84,599)

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($64,275)	($83,408)
Adjustments to reconcile net loss to net cash provided by operating activities:	'	'
Depreciation and amortization	131,546	131,797
Stock-based compensation expense	32,203	27,788
Excess tax benefits from stock-based compensation	-2,246	-3,296
Deferred taxes	5,996	-31,537
Asset impairment charges	2,134	10,504
Other losses (gains), net	3,214	-915
Changes in operating assets and liabilities, net of business combinations:	'	'
Accounts receivable, net	-22,287	10,966
Prepaid expenses and other assets	-16,180	-25,330
Accounts payable	13,651	8,707
Accrued expenses	-22,120	-8,981
Accrued compensation and benefits	-24,896	12,313
Deferred revenue	20,732	23,169
Other liabilities	-5,469	-8,466
Net cash provided by operating activities	52,003	63,311
Cash flows from investing activities:	'	'
Capital expenditures	-20,656	-56,988
Capitalized software	-28,318	-30,462
Cash paid for business acquisitions, net of cash acquired	-20,180	-148,875
Purchases of marketable securities, other investments and related intangible assets	-21,544	0
Sales and maturities of other investments	39	12,855
Proceeds from sale of fixed assets	86	0
Net cash used in investing activities	-90,573	-223,470
Cash flows from financing activities:	'	'
Proceeds from issuance 1.25% senior cash convertible notes, net of issuance costs	0	336,962
Purchase of call option related to 1.25% senior cash convertible notes	0	-82,800
Proceeds from issuance of warrants, net of issuance costs	0	51,208
Proceeds from issuance of common stock	1,670	11,256
Excess tax benefits from stock-based compensation	2,246	3,296
Taxes paid related to net share settlement of equity awards	-8,891	-7,884
Payments of capital lease obligations	-337	-416
Payments of acquisition financing obligations	0	-29,671
Credit facility payments	-73,751	-574,281
Credit facility borrowings, net of issuance costs	91,964	410,983
Net cash provided by financing activities	12,901	118,653
Effect of exchange rate changes on cash and cash equivalents	60	-1,660
Net decrease in cash and cash equivalents	-25,609	-43,166
Cash and cash equivalents, beginning of period	62,954	103,956
Cash and cash equivalents, end of period	$37,345	$60,790

CONSOLIDATED_STATEMENTS_OF_CAS1

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) (Senior cash convertible notes [Member])	Sep. 30, 2014	Sep. 30, 2013
Senior cash convertible notes [Member]	'	'
Debt instrument interest rate	1.25%	1.25%

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	1. Summary of Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” or “our” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries, unless otherwise stated.
	Basis of Presentation
	The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2014 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014.
	Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted pursuant to the SEC’s rules and regulations for interim reporting. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2013 (our “Form 10-K”).
	Use of Estimates
	The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates.
	Significant Accounting Policies
	There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.
	Recently Adopted Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued updated authoritative guidance to resolve the diversity in practice about whether FASB Account Standards Codification (“ASC”) Subtopic 810-10, Consolidation—Overall, or ASC Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, this guidance resolves the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. This guidance is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013 and we adopted the new guidance in the first quarter of 2014. The adoption of this accounting guidance had no impact on our consolidated results.
	In July 2013, the FASB issued Accounting Standards Update No. 2013-011, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-011”). ASU 2013-011 provides specific guidance on financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new guidance applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date and states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and we adopted the new guidance prospectively in the first quarter of 2014. The adoption of this accounting guidance resulted in the reclassification, for presentation purposes only, of approximately $4 million from other liabilities to deferred tax assets in our consolidated balance sheet as of September 30, 2014.
	Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASU 2014-09”), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new standard permits the use of either the retrospective or cumulative effect transition methods. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are currently in the process of evaluating this new guidance.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting of a share-based award, and that could be achieved after the requisite service period, be treated as a performance condition. ASU 2014-12 is effective for reporting periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. In addition, entities will have the option of applying the guidance either prospectively (i.e. only to awards granted or modified on or after the effective date of ASU 2014-12) or retrospectively. We are currently evaluating the impact of this accounting guidance, but do not expect it to have any material impact on our consolidated financial statements.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), which requires management of an entity to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events, considered in the aggregate, that raise substantial doubt about such entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable), and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We are currently evaluating the impact of this accounting guidance, but do not expect it to have any material impact on our consolidated financial statements.
	We do not believe that any other recently issued, but not yet effective accounting standards, if currently adopted, would have a material impact on our consolidated financial statements.

Business_Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Business Combinations	'
	2. Business Combinations
	Acquisition of Oasis Medical Solutions Limited
	On July 8, 2014, we acquired the entire capital stock of Oasis Medical Solutions Limited (“Oasis”), a privately-held, Patient Administration System and health informatics solutions provider headquartered in London, United Kingdom, for approximately $20.6 million in cash. The preliminary allocation of the fair value of the consideration transferred is as follows: approximately $0.4 million of acquired cash; approximately $5.7 million of accounts receivable and other current assets; approximately $6.3 million of intangible assets related to technology, including Oasis’ tradename; approximately $6.5 million of intangible assets related to customer relationships; goodwill of approximately $10.6 million; approximately $0.2 million of fixed assets; approximately $6.4 million of accounts payable, deferred revenue and accruals; and approximately $2.7 million of net deferred tax liabilities. Goodwill was determined based on the residual difference between the fair value of the consideration transferred and the value assigned to tangible and intangible assets and liabilities, and is not deductible for tax purposes. Among the factors that contributed to a purchase price resulting in the recognition of goodwill were the expected synergies that we believe will result from the integration of our product offerings with those of Oasis. The acquired intangible assets, excluding goodwill, will be amortized on a straight-line basis and have estimated lives of 10 years, with the exception of Oasis’ customer relationships, which have an estimated life of 12 years.
	The pro forma impact of the Oasis acquisition on current and prior quarters, as well as the net revenue and results of operations of Oasis subsequent to its acquisition for the three months ended September 30, 2014, were not material. We did not incur any significant acquisition and integration-related costs related to the Oasis acquisition during the three months ended September 30, 2014.
	Acquisition of dbMotion Ltd.
	On March 4, 2013, we acquired all of the issued and outstanding share capital of dbMotion Ltd. (“dbMotion”), a leading supplier of community health solutions.
	Under the acquisition method of accounting, the fair value of consideration transferred was allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date with the remaining unallocated amount recorded as goodwill. During the three months ended March 31, 2014, we finalized the allocation of the fair value of the consideration transferred, which resulted in an increase of approximately $1.0 million in both the total fair value of consideration transferred and the residual allocation to goodwill.
	The final fair value of consideration transferred for the dbMotion acquisition is comprised of the following:
		(In thousands)
	Cash	$	140,079
	Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing $12.57 per share		48,061
	Deferred cash consideration payable on the 18-month anniversary of the closing		23,023
	Subordinated promissory note maturing 18 months following the closing		6,648
	Fair value of Allscripts’ previous interest in dbMotion		8,367
	Total fair value of consideration transferred	$	226,178
	The allocation of the fair value of the consideration transferred, including all measurement period adjustments, is as follows:
		(In thousands)
	Acquired cash and cash equivalents, and restricted cash	$	14,188
	Accounts receivable, net		3,226
	Prepaid expenses and other current assets		574
	Fixed assets and other long-term assets		1,449
	Goodwill		137,649
	Intangible assets		85,450
	Accounts payable and accrued liabilities		(10,560	)
	Deferred taxes, net		(36	)
	Deferred revenue		(5,100	)
	Other liabilities		(662	)
	Net assets acquired	$	226,178
	Acquisition costs related to the dbMotion acquisition are included in selling, general and administrative expenses and totaled approximately $0.8 million and $1.8 million for the three months ended September 30, 2014 and 2013, respectively, and approximately $3.6 million and $6.0 million for the nine months ended September 30, 2014 and 2013, respectively. These costs include employee compensation costs of approximately $0.8 million and $1.8 million for the three months ended September 30, 2014 and 2013, respectively, approximately $3.6 million and $4.2 million for the nine months ended September 30, 2014 and 2013, respectively; and $0.5 million of seller transaction costs for the nine months ended September 30, 2013. In addition, we incurred $2.4 million and $5.5 million for the three and nine months ended September 30, 2013, respectively, related to product consolidation activities, which are included in asset impairment charges.
	The revenue and net loss of dbMotion since March 4, 2013 included in our consolidated statement of operations for the three and nine months ended September 30, 2013, and the supplemental pro forma revenue and net loss of the combined entity, are as follows:
	(In thousands)	Three Months			Nine Months
		Ended			Ended
		September 30,			September 30,
		2013			2013
		(Unaudited)			(Unaudited)
	Actual from dbMotion since acquisition date of March 4, 2013:
	Revenue	$	124		$	852
	Net loss	($	9,579	)	($	21,119	)
	Supplemental pro forma data for combined entity:
	Revenue	$	331,527		$	1,025,951
	Net loss	($	47,139	)	($	86,667	)
	Net loss per share, basic and diluted	($	0.26	)	($	0.49	)
	The unaudited supplemental pro forma data has been calculated after applying our accounting policies and adjusting the results of dbMotion to reflect the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant and equipment and intangible assets had been applied on January 1, 2012, together with the consequential tax effects. Supplemental pro forma results for the three and nine months ended September 30, 2013 were adjusted to exclude acquisition-related costs incurred during the periods as well as the nonrecurring gain related to the fair value adjustment of our prior cost method investment in dbMotion. The effects of transactions between us and dbMotion during the periods presented have been eliminated.
	Amortization of software development and acquisition-related assets in our consolidated statement of operations for the three and nine months ended September 30, 2014 includes approximately ($0.1) million and ($0.4) million, respectively, related to the acquisition of dbMotion, which is attributable to professional services cost of revenue. Amortization of software development and acquisition-related assets in our consolidated statement of operations for the three and nine months ended September 30, 2013 includes approximately $2.9 million and $4.7 million, respectively, related to the acquisition of dbMotion, which is attributable to cost of revenue as follows: approximately $1.0 million and $1.7 million, respectively, related to system sales; approximately $1.1 million and $1.2 million, respectively, related to professional services, and approximately $0.8 million and $1.8 million, respectively, related to maintenance.
	Acquisition of Jardogs LLC
	Also on March 4, 2013, we acquired substantially all of the assets of Jardogs LLC (“Jardogs”), the developer of FollowMyHealth, a highly-rated, cloud-based patient engagement solution provider, for $24 million in cash. During the three months ended March 31, 2014, we finalized the allocation of the Jardogs purchase price, resulting in no additional measurement period adjustments to the fair values of the assets and liabilities acquired as disclosed in our Form 10-K.
	The pro forma impact of the Jardogs acquisition on current and prior quarters, as well as the net revenue and operating losses generated by Jardogs subsequent to its acquisition for the three and nine months ended September 30, 2013, were not material. Acquisition and integration-related costs related to the Jardogs acquisition are included in selling, general and administrative expenses and totaled approximately $0.7 million for the nine months ended September 30, 2013. We did not incur any significant acquisition and integration-related costs related to the Jardogs acquisition during the three months ended September 30, 2013 or during the three and nine months ended September 30, 2014.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	3. Fair Value Measurements
	Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories:
	Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Our Level 1 investments include money market funds valued daily by the fund companies, and the valuation is based on the publicly reported net asset value of each fund.
	Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar instruments in active markets, and inputs other than quoted prices that are observable for the asset or liability. Our Level 2 non-derivative investments include marketable securities and consist of mortgage and asset-backed bonds. Marketable securities are recorded at fair value determined using a market approach, based on prices and other relevant information generated by market transactions involving identical or comparable assets which are considered to be Level 2 inputs. Our Level 2 derivative financial instrument is an interest rate swap contract which is valued based upon observable values for underlying interest rates and market determined risk premiums.
	Level 3: Inputs are unobservable for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option (as defined in Note 10, “Derivative Financial Instruments,”) asset and the embedded cash conversion option liability. Refer to Note 8, “Debt,” and Note 10, “Derivative Financial Instruments,” for further information regarding our derivative financial instruments. These derivatives are not actively traded and are valued based on an option pricing model that uses observable and unobservable market data for inputs. Significant market data inputs used to determine the fair value as of September 30, 2014 and December 31, 2013 included our common stock price, time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. The 1.25% Call Option asset and the embedded cash conversion option liability were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is substantially mitigated.
	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:
		Balance Sheet	September 30, 2014											December 31, 2013
	(In thousands)	Classifications	Level 1		Level 2			Level 3			Total			Level 1		Level 2			Level 3			Total
	Money market funds	Cash equivalents	$	0	$	0		$	0		$	0		$	3,634	$	0		$	0		$	3,634
	Marketable securities	Long-term marketable securities		0		1,321			0			1,321			0		1,329			0			1,329
	1.25% Call Option	Other assets		0		0			67,677			67,677			0		0			104,656			104,656
	Cash conversion option	Other liabilities		0		0			(68,491	)		(68,491	)		0		0			(105,637	)		(105,637	)
	Interest rate swap	Other liabilities		0		(31	)		0			(31	)		0		(458	)		0			(458	)
	Total		$	0	$	1,290		($	814	)	$	476		$	3,634	$	871		($	981	)	$	3,524
	During the first quarter of 2014, we acquired certain non-marketable equity securities of a third party and entered into a commercial agreement with the third party to license and distribute its products and services for total consideration of approximately $6.0 million. The equity investment and commercial agreement were valued at approximately $4.1 million and $1.9 million, respectively. During the second and third quarters of 2014, we acquired certain non-marketable equity securities of three other third parties for total consideration of approximately $15.1 million. Of the four equity investments acquired during the nine months ended September 30, 2014, three are accounted for under the cost method, and one is accounted for under the equity method. The carrying values of the cost method investments and the equity method investment of approximately $17.8 million and $1.4 million, respectively, are included in other assets and the carrying value of the above-referenced commercial agreement is included in intangible assets, net, in the accompanying consolidated balance sheet as of September 30, 2014. As of December 31, 2013, our outstanding investments in non-marketable equity securities were not material.
	Our long-term financial liabilities include amounts outstanding under our senior secured credit facility, with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) also approximates fair value as of September 30, 2014, since the effective interest rate on the 1.25% Notes also approximates current market rates. See Note 8, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	4. Stockholders’ Equity
	Stock-based Awards
	We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the appropriate service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved.
	The fair value of service-based restricted stock units and restricted stock awards is measured at their underlying closing share price on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. The fair value of stock options granted during the three and nine months ended September 30, 2013 was determined using the Black-Scholes-Merton valuation model and reflects the below input assumptions. During the three and nine months ended September 30, 2013, approximately 0.2 million and 3.8 million stock options, respectively, were granted. No stock options were granted during the three and nine months ended September 30, 2014.
		Three Months			Nine Months
		Ended			Ended
		September 30,			September 30,
		2013			2013
	Weighed-average exercise price	$	15.22		$	13.78
	Expected term (in years)		4.75			4.75
	Expected volatility		48	%		54.9	%
	Expected dividend yield		0	%		0	%
	Risk-free interest rate		1.4	%		0.8	%
	Stock-based compensation expense recognized during the three and nine months ended September 30, 2014 and 2013 is included in our consolidated statements of operations as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(In thousands)	2014			2013			2014		2013
	Cost of revenue:
	Professional services	$	622		$	607		$	2,086	$	1,924
	Maintenance		285			313			1,084		1,116
	Transaction processing and other		428			372			1,550		1,271
	Total cost of revenue		1,335			1,292			4,720		4,311
	Selling, general and administrative expenses		7,881			6,606			20,999		17,418
	Research and development		839			1,780			6,484		6,059
	Total stock-based compensation expense	$	10,055		$	9,678		$	32,203	$	27,788
	No stock-based compensation costs were capitalized during the three and nine months ended September 30, 2014 and 2013.
	During the three and nine months ended September 30, 2014, we granted the following stock-based awards:
		Three Months Ended September 30, 2014						Nine Months Ended September 30, 2014
	(In thousands, except per share amounts)	Shares			Weighted-Average			Shares		Weighted-Average
					Grant Date					Grant Date
					Fair Value					Fair Value
	Service-based restricted stock units		13		$	14.91			1,453	$	18.09
	Performance-based restricted stock units with a service condition		0		$	0			467	$	18.51
	Market-based restricted stock units with a service condition		0		$	0			221	$	14.36
			13		$	14.91			2,141	$	17.79
	During the nine months ended September 30, 2014 and the year ended December 31, 2013, approximately 1.4 million and 2.6 million shares of stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards.
	Stock Repurchases
	The stock repurchase program approved by the Board of Directors of Allscripts Healthcare Solutions, Inc. (the “Board”) in April 2011 expired on May 9, 2014. No shares were repurchased under this program during the six months ended June 30, 2014 and the year ended December 31, 2013. As of the date of this report, there is no current authorization.
	Net Share-settlements
	Beginning in 2011, upon vesting, restricted stock units and awards are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested in 2014 and 2013 were net-share settled such that we withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees’ minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the nine months ended September 30, 2014 and 2013 were approximately 549 thousand and 564 thousand, respectively, and were based on the value of the restricted stock units and awards on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting.
	Issuance of Warrants
	In June 2013, we agreed to issue a warrant to a commercial partner as part of an overall commercial relationship pursuant to which the warrant holder has the right to purchase 1.5 million shares of our common stock at a strike price of $12.94 per share. The warrant vests in four equal annual installments of 375 thousand shares (beginning in June 2014) and expires in June 2020. Our issuance of the warrant was a private placement exempt from registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. This warrant is not actively traded and is valued based on an option pricing model that uses observable and unobservable market data for inputs. During the three and nine months ended September 30, 2014, we recognized approximately $0.6 million and $1.9 million, respectively, of the fair value of the warrant as a reduction to transaction processing and other revenue. During the three and nine months ended September 30, 2013, we recognized approximately $0.8 million of the fair value of the warrant as a reduction to transaction processing and other revenue.

Earnings_Loss_Per_Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings (Loss) Per Share	'
	5. Earnings (Loss) Per Share
	Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method.
	The calculations of earnings (loss) per share are as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(In thousands, except per share amounts)	2014			2013			2014			2013
	Basic Loss per Common Share:
	Net loss	($	25,763	)	($	48,940	)	($	64,275	)	($	83,408	)
	Net loss available to common stockholders	($	25,763	)	($	48,940	)	($	64,275	)	($	83,408	)
	Weighted-average common shares outstanding		180,189			178,166			179,691			176,517
	Basic Loss per Common Share	($	0.15	)	($	0.27	)	($	0.36	)	($	0.47	)
	Diluted Loss per Common Share:
	Net loss	($	25,763	)	($	48,940	)	($	64,275	)	($	83,408	)
	Net loss available to common stockholders	($	25,763	)	($	48,940	)	($	64,275	)	($	83,408	)
	Weighted-average common shares outstanding		180,189			178,166			179,691			176,517
	Dilutive effect of stock options, restricted stock unit awards and warrants		0			0			0			0
	Weighted-average common shares outstanding assuming dilution		180,189			178,166			179,691			176,517
	Diluted Loss per Common Share	($	0.15	)	($	0.27	)	($	0.36	)	($	0.47	)
	As a result of our net loss available to common stockholders for the three and nine months ended September 30, 2014 and 2013, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for each of these periods, since the inclusion of any stock equivalents would be anti-dilutive.
	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted (loss) earnings per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(In thousands)	2014			2013			2014			2013
	Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation		24,117			24,839			24,314			11,388

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	6. Goodwill and Intangible Assets
	Goodwill and intangible assets consist of the following:
		September 30, 2014								December 31, 2013
	(In thousands)	Gross			Accumulated			Intangible		Gross			Accumulated			Intangible
		Carrying			Amortization			Assets, Net		Carrying			Amortization			Assets, Net
		Amount								Amount
	Intangibles subject to amortization
	Proprietary technology	$	451,320		($	258,511	)	$	192,809	$	445,960		($	231,634	)	$	214,326
	Customer contracts and relationships		550,895			(373,512	)		177,383		542,205			(352,560	)		189,645
	Total	$	1,002,215		($	632,023	)	$	370,192	$	988,165		($	584,194	)	$	403,971
	Intangibles not subject to amortization
	Registered trademarks							$	52,000							$	52,000
	Goodwill								1,200,651								1,189,585
	Total							$	1,252,651							$	1,241,585
	During the three months ended September 30, 2014, in connection with our acquisition of Oasis, we recognized additional goodwill of $10.6 million, which remains subject to future adjustments before the close of the measurement period. In addition, during the three months ended March 31, 2014, we finalized the allocation of the fair value of the consideration we paid in connection with our acquisitions of dbMotion and Jardogs, which resulted in the recognition of additional goodwill of approximately $1.0 million. Refer to Note 2, “Business Combinations,” for additional information regarding these acquisitions and the measurement period adjustment recorded during the three months ended March 31, 2014. Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2014 were as follows:
	(In thousands)	Clinical and			Population			Managed		Total
		Financial Solutions			Health			Services
	Balance as of December 31, 2013	$	625,769		$	425,216		$	138,600	$	1,189,585
	Additions arising from business acquisitions:
	Oasis		10,568			0			0		10,568
	dbMotion		0			1,018			0		1,018
	Total additions to goodwill		10,568			1,018			0		11,586
	Impairment of goodwill		0			0			0		0
	Foreign exchange translation		(520	)		0			0		(520	)
	Balance as of September 30, 2014	$	635,817		$	426,234		$	138,600	$	1,200,651
	There were no accumulated impairment losses associated with our goodwill as of September 30, 2014 or December 31, 2013.

Asset_Impairment_Charges

Asset Impairment Charges	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Asset Impairment Charges	'
	7. Asset Impairment Charges
	In October 2012, we initiated a MyWay convergence program. Since that time, we have been upgrading those MyWay clients who have elected to upgrade to Professional Suite, at no additional cost to these clients. As a result, we recorded non-cash charges to earnings of approximately $5.0 million during the three and nine months ended September 30, 2013, and $0.2 million and $0.7 million during the three and nine months ended September 30, 2014, which were related to the write-off of certain MyWay-related deferred costs, and which were determined to be unrealizable. During the nine months ended September 30, 2014, we also recorded $1.4 million of non-cash capitalized software impairment charges as a result of our decision to discontinue several software development projects. During the three and nine months ended September 30, 2013, we also recorded non-cash charges of $2.4 million and $5.5 million, respectively, primarily related to product consolidation activities associated with the dbMotion acquisition.
		Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)	2014		2013		2014		2013
	Asset impairment charges	$	188	$	7,371	$	2,134	$	10,504

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	8. Debt
	Debt outstanding, excluding capital leases, consisted of the following:
			September 30, 2014						December 31, 2013
	(In thousands)		Principal		Unamortized		Net		Principal		Unamortized		Net
			Balance		Discount		Carrying		Balance		Discount		Carrying
							Amount						Amount
	1.25% Cash Convertible Senior Notes		$	345,000	$	69,873	$	275,127	$	345,000	$	77,529	$	267,471
	Senior Secured Credit Facilities (long-term portion)			289,054		1,662		287,392		280,000		2,338		277,662
	Senior Secured Credit Facilities (current portion)			25,313		915		24,398		16,875		982		15,893
	Total debt		$	659,367	$	72,450	$	586,917	$	641,875	$	80,849	$	561,026
	Interest expense consisted of the following:
			Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)		2014		2013		2014		2013
	Interest expense		$	4,190	$	3,653	$	12,074	$	10,918
	Amortization of discounts			2,842		2,732		8,400		3,055
	Amortization of debt issuance costs			510		510		1,531		3,157
	Write off of unamortized deferred debt issuance costs			0		0		0		3,901
	Total interest expense		$	7,542	$	6,895	$	22,005	$	21,031
	Interest expense related to the 1.25% Notes was comprised of the following:
			Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)		2014		2013		2014		2013
	Coupon interest at 1.25%		$	1,078	$	1,078	$	3,234	$	1,234
	Amortization of original issuance discount			2,598		2,474		7,656		2,797
	Amortization of debt issuance costs			295		295		885		344
	Total interest expense related to the 1.25% Notes		$	3,971	$	3,847	$	11,775	$	4,375
	There have been no significant changes in our senior secured credit facility agreement from those disclosed in our Form 10-K. As of September 30, 2014, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount.
	As of September 30, 2014, $208.1 million under a term loan, $106.3 million under a revolving credit facility, and $0.9 million in letters of credit were outstanding under our senior secured credit facility. As of September 30, 2014, the interest rate on the senior secured credit facility was LIBOR plus 2.75%, which totaled 2.90%. Refer to Note 10, “Derivative Financial Instruments,” for a discussion of our interest rate swap agreement. We were in compliance with all covenants under our senior secured credit facility agreement as of September 30, 2014. Unamortized deferred debt issuance costs total $10.0 million and are included within other assets on the consolidated balance sheet as of September 30, 2014.
	As of September 30, 2014, we had $317.3 million available, net of outstanding letters of credit, under our revolving credit facility. There can be no assurance that we will be able to draw on the full available balance of our senior secured credit facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings.
	The following table summarizes our future principal payment obligations under the 1.25% Notes and the senior secured credit facility as of September 30, 2014:
	(In thousands)		Total		Remainder of		2015		2016		2017		2018		Thereafter
					2014
	1.25% Cash Convertible Senior Notes (1)		$	345,000	$	0	$	0	$	0	$	0	$	0	$	345,000
	Senior Secured Term Loan		$	208,125		5,625		28,125		39,375		50,625		84,375		0
	Senior Secured Revolving Facility		$	106,242		0		0		0		0		106,242		0
			$	659,367	$	5,625	$	28,125	$	39,375	$	50,625	$	190,617	$	345,000
	-1	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	9. Income Taxes
	The provision for income taxes reflects our estimate of the effective tax rate expected to be applicable for the full year. To the extent that actual pre-tax results for the year differ from the forecasted estimates applied at the end of the most recent interim period, the actual tax rate recognized during calendar 2014 could be different from the forecast rate. Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance, income attributable to foreign jurisdictions taxed at lower rates, state taxes, permanent differences, and certain discrete items. The effective tax rates were as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(Dollar amounts in thousands)	2014			2013			2014			2013
	Loss before income taxes	($	26,211	)	($	51,173	)	($	61,480	)	($	113,564	)
	Income tax benefit (provision)	$	448		$	2,233		($	2,795	)	$	30,156
	Effective tax rate		1.7	%		4.4	%		(4.5	%)		26.6	%
	Our effective tax rate for the three and nine months ended September 30, 2014 was lower compared with the prior year comparable periods primarily due to the impact of an approximately $6.3 million and $24.1 million valuation allowance recorded during the three and nine months ended September 30, 2014, respectively, against federal net operating loss and credit carryforwards. In addition, the U.S. research and development credit had not been extended as of September 30, 2014 for the 2014 tax year and, therefore, no estimate for this credit has been included in the effective tax rate as of September 30, 2014. The tax benefit recorded during the three and nine months ended September 30, 2013 included the impacts of both the 2012 and 2013 research and development credits.
	In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and current year actual and projected results of operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). The additional valuation allowance recorded during the three and nine months ended September 30, 2014 related to deferred tax assets associated with net operating loss carryforwards.
	Our unrecognized income tax benefits were $15.4 million and $18.3 million as of September 30, 2014 and December 31, 2013, respectively. The decrease was attributable to the timing of a tax deduction item taken in a prior period and a settlement with a taxing authority. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

Derivative_Financial_Instrumen

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Financial Instruments	'
	10. Derivative Financial Instruments
	1.25% Call Option
	Concurrent with the issuance of the 1.25% Notes in June 2013, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes.
	The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to the cash settlement features until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 3, “Fair Value Measurements.” The fair value of the 1.25% Call Option at September 30, 2014 and December 31, 2013 was approximately $67.7 million and $104.7 million, respectively.
	The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in other income, net. For the three and nine months ended September 30, 2014, the change in the fair value of the 1.25% Call Option resulted in net losses of $35.4 million and $37.0 million, respectively. For the three and nine months ended September 30, 2013 the change in the fair value of the 1.25% Call Option resulted in net gains of $21.4 million and $19.7 million, respectively. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal.
	1.25% Notes Embedded Cash Conversion Option
	The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 3, “Fair Value Measurements.” The fair value of the embedded cash conversion option at September 30, 2014 and December 31, 2013 was approximately $68.4 million and $105.6 million, respectively. For the three and nine months ended September 30, 2014, the change in the fair value of the embedded cash conversion option resulted in net gains of $35.6 million and $37.2 million, respectively. For the three and nine months ended September 30, 2013, the change in the fair value of the embedded cash conversion option resulted in net losses of $22.3 million and $20.6 million, respectively. The net gains recognized for the three and nine months ended September 30, 2014 were slightly higher than the losses recognized on the 1.25% Call Option over the same periods.
	Interest Rate Swap Agreement
	We entered into an interest rate swap agreement with an effective date of October 29, 2010 that has the economic effect of modifying the variable rate component of the interest obligations associated with a portion of our variable rate debt. The initial notional amount of the interest rate swap agreement was $300 million, with scheduled step downs over time, and an expiration date of October 31, 2014. As of September 30, 2014, the notional amount of the interest rate swap agreement was $50 million. The interest rate swap agreement converts the one-month LIBOR rate on the corresponding notional amount of debt to an effective fixed rate of 0.896% (exclusive of the applicable margin currently charged under the Senior Secured Credit Facility). The critical terms of the interest rate swap agreement and the related debt agreement match and allow us to designate the interest rate swap agreement as a highly effective cash flow hedge under GAAP. The interest rate swap agreement is designed to protect us against changes in interest payments due to benchmark interest rate movements. The change in fair value of this interest rate swap agreement is recognized in other comprehensive (loss) income with the corresponding amounts included in other assets or other liabilities in our consolidated balance sheets. Amounts accumulated in other comprehensive (loss) income are indirectly recognized in earnings as periodic settlements of the swap occur and the fair value of the swap declines to zero as it nears expiration.
	The fair value of our interest rate swap was approximately zero and a liability of $0.5 million as of September 30, 2014 and December 31, 2013, respectively. We recognized the following activity related to our interest rate swap agreement:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(In thousands)	2014			2013			2014			2013
	Effective portion
	Current period increase in fair value recognized in other comprehensive (loss) income, net	$	110		$	207		$	427		$	856
	Tax effect		(43	)		(82	)		(168	)		(334	)
	Net	$	67		$	125		$	259		$	522
	Loss reclassified from accumulated other comprehensive loss to interest expense	$	110		$	286		$	465		$	968
	Amount excluded from effectiveness assessment and ineffective gain (loss) recognized in other income (expense), net	$	0		$	0		$	0		$	0
	The amount of interest rate swap derivative losses included in accumulated other comprehensive loss that will be reclassified into earnings during October 2014 is not material. No gains (losses) were reclassified from accumulated other comprehensive loss into earnings as a result of forecasted transactions that failed to occur during the three and nine months ended September 30, 2014 and 2013.

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	11. Contingencies
	In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated, certain of which are discussed below. We intend to vigorously defend ourselves in these matters.
	No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made.
	The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. If one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients, which could further adversely affect our operating results.
	In the opinion of our management, based on the information currently available, there was not at least a reasonable possibility that we may have incurred a material loss, or a material loss in excess of a recorded accrual, with respect to the following matters.
	On September 14, 2010, Pegasus Imaging Corporation filed a complaint against us in the Circuit Court of the Thirteenth Judicial Circuit of the State of Florida in and for Hillsborough County, Florida, which we transferred to the Special Superior Court for Complex Business Cases. The lawsuit also named former officers Jeffrey Amrein and John Reinhart as defendants. The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations, and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud, and negligence. On June 27, 2013, we filed our First Amended Answer, Defenses, and Counterclaims to the plaintiff’s Second Amended Complaint, denying all material allegations, and asserting counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation. On July 7, 2014, the Court granted our motion for summary judgment on the plaintiff’s claim of unfair trade practices under Florida law and our motion for summary judgment as to the aforementioned defunct corporations, and granted the plaintiff’s motion for summary judgment on our counterclaims. No trial date has been scheduled.
	On January 30, 2013, Costco Wholesale Corporation made a demand for arbitration against us with the International Institute for Conflict Resolution in connection with our offer to upgrade our MyWay clients to Professional Suite. The demand for arbitration seeks certain equitable relief in connection with the upgrade offer and also seeks damages for breach of contract and breach of an alleged duty of good faith and fair dealing. No arbitration date has been scheduled.
	On February 26, 2013, a lawsuit was filed by Cardinal Health 200, LLC against us in the Court of Common Pleas for Franklin County, Ohio. The complaint seeks damages of no less than $3,978,000 for alleged breaches of contract by us in connection with our offer to upgrade our MyWay clients to Professional Suite, as well as other equitable relief. The complaint alternatively seeks a declaration that we invalidly terminated our agreement with the plaintiff. The case is currently scheduled for trial in June 2015.
	In the opinion of our management, based on the information currently available, there is a reasonable possibility that we may incur a material loss with respect to the following matters. However, it is not possible to estimate the possible loss or range of loss at this time. Our management will continue to evaluate the potential exposure related to these matters in future periods.
	On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in U.S. District Court for the Northern District of Illinois against us. The complaint alleges that on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff seeks $500 for each alleged violation of the TCPA; treble damages if the Court finds the violations to be willful, knowing or intentional; and injunctive and other relief. Discovery is proceeding. The plaintiff’s deadline to file a motion for class certification is June 2015. No trial date has been scheduled.
	On May 2, 2012, a lawsuit was filed in the United States District Court for the Northern District of Illinois against us; Glen Tullman, our former Chief Executive Officer; and William Davis, our former Chief Financial Officer, by the Bristol County Retirement System for itself and on behalf of a purported class consisting of stockholders who purchased our common stock between November 18, 2010 and April 26, 2012. The plaintiffs later added Lee Shapiro, our former President, as a defendant. The plaintiffs allege that we, Mr. Tullman, Mr. Davis and Mr. Shapiro made materially false and misleading statements and/or omissions during the putative class period regarding our progress in integrating our business with the business of Eclipsys Corporation following the two companies’ August 24, 2010 merger, and that we lacked a reasonable basis for certain statements regarding those post-merger integration efforts as well as our operations and results and projections of future financial performance. A fully-briefed motion to dismiss is pending. No trial date has been scheduled.
	On June 27, 2012, a purported shareholder, Richard Devereaux, filed a shareholder derivative action in the Circuit Court of Cook County, Illinois against us; Glen Tullman, our former Chief Executive Officer; William Davis, our former Chief Financial Officer; Paul Black, our current Chief Executive Officer and a current member of the Board; and Dennis Chookaszian, Robert Cindrich, Marcel Gamache, Philip Green, and Michael Kluger, each of whom are or were members of the Board. The suit alleges breach of fiduciary duties and unjust enrichment against certain of our former and current executives who allegedly made misleading claims about our business and financial condition, which allegedly caused our stock price to be artificially inflated and then drop sharply when we reported earnings below expectations and disclosed a “leadership dispute” in a regulatory filing. The case is currently stayed by agreement of the parties.
	On July 11, 2012, RLIS, Inc. filed a complaint in the United States District Court for the Southern District of Texas against us. The complaint alleges, among other things, that our Enterprise EHR product (now Allscripts Touchworks) willfully infringes U.S. Patent No. 7,076,436. On September 28, 2012, the plaintiff filed an amended complaint that alleges, among other things, that certain of our products and services infringe both the foregoing patent as well as U.S. Patent No. 5,823,940. The amended complaint seeks an unspecified amount of damages and interest, as well as injunctive relief. The case is currently scheduled for trial in March 2015.
	On May 15, 2014, Medfusion, Inc. filed a complaint in the Superior Court of Wake County, North Carolina, against us. The complaint alleges, among other things, breach of contract, fraudulent inducement, fraud, and violation of North Carolina’s unfair methods of competition and unfair or deceptive trade practices statues by us in connection with a previous commercial agreement between the parties. The complaint seeks an unspecified amount of damages and interest. No trial date has been scheduled.
	Other Matters
	During the third quarter of 2014 and subsequently, we resolved a number of pending legal proceedings related to our offer to upgrade MyWay clients to Professional Suite. We paid approximately $9.8 million in connection with the resolution of certain of these claims during the third quarter of 2014. In August 2014, we concluded our arbitration with Etransmedia Technology, Inc. In October 2014, we entered into a settlement agreement with Pain Clinic of Northwest Florida, Inc., American Pain Care Specialists, LLC, Advanced Pain Specialists, Inc., and South Baldwin Family Practice, LLC. A final hearing to approve the settlement agreement, which has been preliminarily approved by the court, is scheduled for February 2015.

Business_Segments

Business Segments	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Business Segments	'
	12. Business Segments
	We primarily derive our revenue from sales of our proprietary software and related hardware, professional services and IT outsourcing services. These sales are also the basis for our recurring service contracts for software maintenance and certain transaction processing services. We revised our reportable segments effective December 1, 2013, in connection with changes to our organizational and management structure that were announced earlier in 2013. Prior to this change, we used five reportable segments: Software Delivery, Services Delivery, Client Support, Pathway Solutions and IT Outsourcing.
	The changes to our organizational and management structure were aimed at improving our operational effectiveness, enhancing our competitiveness and creating a greater focus on client needs. These changes, which involved the creation of strategic business units, were designed to transition us towards a flatter business unit model aligned with key products and services, and away from a functional organization. After the finalization of these changes and based upon the information used by our Chief Operating Decision Maker (our “CODM”) for making operating decisions and assessing performance, we identified nine operating segments, which were aggregated into three reportable segments: Clinical and Financial Solutions, Population Health, and Managed Services.
	The Clinical and Financial Solutions segment includes our Acute, TouchWorks, Professional Practices, Payer and Life Sciences, and International strategic business units. This segment derives its revenue from the sale of integrated clinical software applications, financial and information solutions, and related installation and maintenance services, to physician practices, hospitals and health systems of various sizes. These solutions primarily include Electronic Health Record-related software, financial and practice management software, related installation and training services, and electronic claims administration services. The Population Health segment includes our Performance and Care Logistics and Population Health strategic business units. This segment derives its revenue from the sale of health management solutions, which are mainly targeted at hospitals, health systems and Accountable Care Organizations, and which enable such organizations to connect, transition, analyze, and coordinate care across the entire care community. The Managed Services segment includes our Outsourcing and Remote Hosting strategic business units. It derives its revenue from the sale of outsourcing solutions, where we assume partial to total responsibility for a healthcare organization’s IT operations, and remote hosting solutions. The revenue from this segment are primarily reflected as part of transaction processing and other in our consolidated statements of operations. Segment data for prior periods presented in the table below has been restated to conform to the current year’s presentation.
	Our CODM uses segment revenue, gross profit and income from operations as measures of performance and to allocate resources. In determining revenue, gross profit and income from operations for our segments, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenue acquired in a business acquisition; and we exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting, and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed. In addition, the “Unallocated Amounts” category includes revenue and the associated cost from the resale of certain ancillary products, primarily consisting of hardware. We do not track our assets by segment.
		Three Months Ended September 30,						Nine Months Ended September 30,
	(In thousands)	2014			2013			2014			2013
	Revenue:
	Clinical and Financial Solutions	$	207,207		$	208,554		$	627,075		$	647,035
	Population Health		71,828			64,006			211,922			189,889
	Managed Services		63,674			53,230			188,586			166,388
	Unallocated Amounts		2,680			4,401			9,387			18,772
	Total revenue	$	345,389		$	330,191		$	1,036,970		$	1,022,084
	Gross Profit:
	Clinical and Financial Solutions	$	99,241		$	95,867		$	299,998		$	302,432
	Population Health		46,975			45,728			143,548			126,069
	Managed Services		1,048			4,161			12,861			16,437
	Unallocated Amounts		(15,808	)		(20,209	)		(46,777	)		(48,681	)
	Total gross profit	$	131,456		$	125,547		$	409,630		$	396,257
	Income (Loss) from operations:
	Clinical and Financial Solutions	$	47,987		$	34,980		$	139,107		$	121,545
	Population Health		26,950			30,240			77,349			74,824
	Managed Services		1,048			4,161			12,861			16,437
	Unallocated Amounts		(94,825	)		(112,833	)		(269,161	)		(312,862	)
	Total loss from operations	($	18,840	)	($	43,452	)	($	39,844	)	($	100,056	)

North_American_Site_Consolidat

North American Site Consolidation Plan	9 Months Ended
	Sep. 30, 2014
Restructuring and Related Activities [Abstract]	'
North American Site Consolidation Plan	'
	13. North American Site Consolidation Plan
	On February 18, 2013, we announced a North American site consolidation plan (the “Site Consolidation Plan”) designed to create a more simplified and efficient organization that is aligned more closely with our business priorities. The Site Consolidation Plan included the closing of twelve offices and one warehouse in conjunction with changes to our corporate operating models intended to reduce costs associated with product solutions development. The costs of implementing these changes primarily consist of employee severance and relocation costs.
	During the three and nine months ended September 30, 2014, we recognized benefits of approximately $0.1 million and $2.2 million, respectively, due to the release of previously accrued severance costs which we no longer expect to pay; while during the three and nine months ended September 30, 2013, we incurred approximately $3.4 million and $17.2 million, respectively, in severance, retention bonuses and relocation expenses resulting from the Site Consolidation Plan. These amounts are included in selling, general and administrative expenses in our consolidated statements of operations for the three and nine months ended September 30, 2014 and 2013, respectively, with the exception of $1.9 million and $2.6 million for the three and nine months ended September 30, 2013, respectively, which are included in research and development. The portion of these amounts allocable to our reportable segments is not material. In the first quarter of 2013, we established a liability for approximately $11.2 million for severance costs resulting from the Site Consolidation Plan, of which approximately $4.2 million remained as of December 31, 2013. During the nine months ended September 30, 2014, we paid approximately $2.0 million and released approximately $2.2 million of previously accrued severance costs, which we no longer expect to pay, resulting in no remaining liability as of September 30, 2014.
	As of September 30, 2014, the Site Consolidation Plan was substantially completed and additional estimated costs yet to be incurred in connection with the Site Consolidation Plan, which primarily consist of lease-related costs, are not expected to be material.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” or “our” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries, unless otherwise stated.
Basis of Presentation	'
	Basis of Presentation
	The unaudited interim consolidated financial statements as of and for the three and nine months ended September 30, 2014 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014.
	Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been omitted pursuant to the SEC’s rules and regulations for interim reporting. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2013 (our “Form 10-K”).
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Significant Accounting Policies	'
	Significant Accounting Policies
	There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.
Recently Adopted Accounting Pronouncements	'
	Recently Adopted Accounting Pronouncements
	In March 2013, the Financial Accounting Standards Board (“FASB”) issued updated authoritative guidance to resolve the diversity in practice about whether FASB Account Standards Codification (“ASC”) Subtopic 810-10, Consolidation—Overall, or ASC Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, this guidance resolves the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. This guidance is effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013 and we adopted the new guidance in the first quarter of 2014. The adoption of this accounting guidance had no impact on our consolidated results.
	In July 2013, the FASB issued Accounting Standards Update No. 2013-011, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (“ASU 2013-011”). ASU 2013-011 provides specific guidance on financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The new guidance applies to all entities with unrecognized tax benefits that also have tax loss or tax credit carryforwards in the same tax jurisdiction as of the reporting date and states that an unrecognized tax benefit in those circumstances should be presented as a reduction to the deferred tax asset. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and we adopted the new guidance prospectively in the first quarter of 2014. The adoption of this accounting guidance resulted in the reclassification, for presentation purposes only, of approximately $4 million from other liabilities to deferred tax assets in our consolidated balance sheet as of September 30, 2014.
Accounting Pronouncements Not Yet Adopted	'
	Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASU 2014-09”), to supersede nearly all existing revenue recognition guidance under GAAP. The core principle of ASU 2014-09 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The new standard permits the use of either the retrospective or cumulative effect transition methods. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. We are currently in the process of evaluating this new guidance.
	In June 2014, the FASB issued Accounting Standards Update No. 2014-12, Compensation — Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (“ASU 2014-12”). ASU 2014-12 requires that a performance target that affects vesting of a share-based award, and that could be achieved after the requisite service period, be treated as a performance condition. ASU 2014-12 is effective for reporting periods and interim periods within those annual periods beginning after December 15, 2015. Early adoption is permitted. In addition, entities will have the option of applying the guidance either prospectively (i.e. only to awards granted or modified on or after the effective date of ASU 2014-12) or retrospectively. We are currently evaluating the impact of this accounting guidance, but do not expect it to have any material impact on our consolidated financial statements.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Presentation of Financial Statements — Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (“ASU 2014-15”), which requires management of an entity to evaluate, in connection with preparing financial statements for each annual and interim reporting period, whether there are conditions or events, considered in the aggregate, that raise substantial doubt about such entity’s ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable), and provide related disclosures. ASU 2014-15 is effective for the annual period ending after December 15, 2016, and for annual and interim periods thereafter. Early adoption is permitted. We are currently evaluating the impact of this accounting guidance, but do not expect it to have any material impact on our consolidated financial statements.
	We do not believe that any other recently issued, but not yet effective accounting standards, if currently adopted, would have a material impact on our consolidated financial statements.

Business_Combinations_Tables

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Final Fair Value of Consideration Transferred for Acquisition	'
	The final fair value of consideration transferred for the dbMotion acquisition is comprised of the following:
		(In thousands)
	Cash	$	140,079
	Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing $12.57 per share		48,061
	Deferred cash consideration payable on the 18-month anniversary of the closing		23,023
	Subordinated promissory note maturing 18 months following the closing		6,648
	Fair value of Allscripts’ previous interest in dbMotion		8,367
	Total fair value of consideration transferred	$	226,178
Assets Acquired and Liabilities Assumed	'
	The allocation of the fair value of the consideration transferred, including all measurement period adjustments, is as follows:
		(In thousands)
	Acquired cash and cash equivalents, and restricted cash	$	14,188
	Accounts receivable, net		3,226
	Prepaid expenses and other current assets		574
	Fixed assets and other long-term assets		1,449
	Goodwill		137,649
	Intangible assets		85,450
	Accounts payable and accrued liabilities		(10,560	)
	Deferred taxes, net		(36	)
	Deferred revenue		(5,100	)
	Other liabilities		(662	)
	Net assets acquired	$	226,178
Proforma Results	'
	The revenue and net loss of dbMotion since March 4, 2013 included in our consolidated statement of operations for the three and nine months ended September 30, 2013, and the supplemental pro forma revenue and net loss of the combined entity, are as follows:
	(In thousands)	Three Months			Nine Months
		Ended			Ended
		September 30,			September 30,
		2013			2013
		(Unaudited)			(Unaudited)
	Actual from dbMotion since acquisition date of March 4, 2013:
	Revenue	$	124		$	852
	Net loss	($	9,579	)	($	21,119	)
	Supplemental pro forma data for combined entity:
	Revenue	$	331,527		$	1,025,951
	Net loss	($	47,139	)	($	86,667	)
	Net loss per share, basic and diluted	($	0.26	)	($	0.49	)

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	'
	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:
		Balance Sheet	September 30, 2014											December 31, 2013
	(In thousands)	Classifications	Level 1		Level 2			Level 3			Total			Level 1		Level 2			Level 3			Total
	Money market funds	Cash equivalents	$	0	$	0		$	0		$	0		$	3,634	$	0		$	0		$	3,634
	Marketable securities	Long-term marketable securities		0		1,321			0			1,321			0		1,329			0			1,329
	1.25% Call Option	Other assets		0		0			67,677			67,677			0		0			104,656			104,656
	Cash conversion option	Other liabilities		0		0			(68,491	)		(68,491	)		0		0			(105,637	)		(105,637	)
	Interest rate swap	Other liabilities		0		(31	)		0			(31	)		0		(458	)		0			(458	)
	Total		$	0	$	1,290		($	814	)	$	476		$	3,634	$	871		($	981	)	$	3,524

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Weighted Average Input Assumptions	'
	The fair value of stock options granted during the three and nine months ended September 30, 2013 was determined using the Black-Scholes-Merton valuation model and reflects the below input assumptions. During the three and nine months ended September 30, 2013, approximately 0.2 million and 3.8 million stock options, respectively, were granted. No stock options were granted during the three and nine months ended September 30, 2014.
		Three Months			Nine Months
		Ended			Ended
		September 30,			September 30,
		2013			2013
	Weighed-average exercise price	$	15.22		$	13.78
	Expected term (in years)		4.75			4.75
	Expected volatility		48	%		54.9	%
	Expected dividend yield		0	%		0	%
	Risk-free interest rate		1.4	%		0.8	%
Stock-Based Compensation Expense	'
	Stock-based compensation expense recognized during the three and nine months ended September 30, 2014 and 2013 is included in our consolidated statements of operations as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(In thousands)	2014			2013			2014		2013
	Cost of revenue:
	Professional services	$	622		$	607		$	2,086	$	1,924
	Maintenance		285			313			1,084		1,116
	Transaction processing and other		428			372			1,550		1,271
	Total cost of revenue		1,335			1,292			4,720		4,311
	Selling, general and administrative expenses		7,881			6,606			20,999		17,418
	Research and development		839			1,780			6,484		6,059
	Total stock-based compensation expense	$	10,055		$	9,678		$	32,203	$	27,788
Stock-Based Awards Granted	'
	During the three and nine months ended September 30, 2014, we granted the following stock-based awards:
		Three Months Ended September 30, 2014						Nine Months Ended September 30, 2014
	(In thousands, except per share amounts)	Shares			Weighted-Average			Shares		Weighted-Average
					Grant Date					Grant Date
					Fair Value					Fair Value
	Service-based restricted stock units		13		$	14.91			1,453	$	18.09
	Performance-based restricted stock units with a service condition		0		$	0			467	$	18.51
	Market-based restricted stock units with a service condition		0		$	0			221	$	14.36
			13		$	14.91			2,141	$	17.79

Earnings_Loss_Per_Share_Tables

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Calculations of Earnings (Loss) Per Share	'
	The calculations of earnings (loss) per share are as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(In thousands, except per share amounts)	2014			2013			2014			2013
	Basic Loss per Common Share:
	Net loss	($	25,763	)	($	48,940	)	($	64,275	)	($	83,408	)
	Net loss available to common stockholders	($	25,763	)	($	48,940	)	($	64,275	)	($	83,408	)
	Weighted-average common shares outstanding		180,189			178,166			179,691			176,517
	Basic Loss per Common Share	($	0.15	)	($	0.27	)	($	0.36	)	($	0.47	)
	Diluted Loss per Common Share:
	Net loss	($	25,763	)	($	48,940	)	($	64,275	)	($	83,408	)
	Net loss available to common stockholders	($	25,763	)	($	48,940	)	($	64,275	)	($	83,408	)
	Weighted-average common shares outstanding		180,189			178,166			179,691			176,517
	Dilutive effect of stock options, restricted stock unit awards and warrants		0			0			0			0
	Weighted-average common shares outstanding assuming dilution		180,189			178,166			179,691			176,517
	Diluted Loss per Common Share	($	0.15	)	($	0.27	)	($	0.36	)	($	0.47	)
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted (Loss) Earnings Per Share	'
	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted (loss) earnings per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(In thousands)	2014			2013			2014			2013
	Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation		24,117			24,839			24,314			11,388

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	Goodwill and intangible assets consist of the following:
		September 30, 2014								December 31, 2013
	(In thousands)	Gross			Accumulated			Intangible		Gross			Accumulated			Intangible
		Carrying			Amortization			Assets, Net		Carrying			Amortization			Assets, Net
		Amount								Amount
	Intangibles subject to amortization
	Proprietary technology	$	451,320		($	258,511	)	$	192,809	$	445,960		($	231,634	)	$	214,326
	Customer contracts and relationships		550,895			(373,512	)		177,383		542,205			(352,560	)		189,645
	Total	$	1,002,215		($	632,023	)	$	370,192	$	988,165		($	584,194	)	$	403,971
	Intangibles not subject to amortization
	Registered trademarks							$	52,000							$	52,000
	Goodwill								1,200,651								1,189,585
	Total							$	1,252,651							$	1,241,585
Changes in Carrying Amount of Goodwill	'
	Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2014 were as follows:
	(In thousands)	Clinical and			Population			Managed		Total
		Financial Solutions			Health			Services
	Balance as of December 31, 2013	$	625,769		$	425,216		$	138,600	$	1,189,585
	Additions arising from business acquisitions:
	Oasis		10,568			0			0		10,568
	dbMotion		0			1,018			0		1,018
	Total additions to goodwill		10,568			1,018			0		11,586
	Impairment of goodwill		0			0			0		0
	Foreign exchange translation		(520	)		0			0		(520	)
	Balance as of September 30, 2014	$	635,817		$	426,234		$	138,600	$	1,200,651

Asset_Impairment_Charges_Table

Asset Impairment Charges (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Asset Impairment Charges	'
		Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)	2014		2013		2014		2013
	Asset impairment charges	$	188	$	7,371	$	2,134	$	10,504

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt Outstanding Excluding Capital Leases	'
	Debt outstanding, excluding capital leases, consisted of the following:
			September 30, 2014						December 31, 2013
	(In thousands)		Principal		Unamortized		Net		Principal		Unamortized		Net
			Balance		Discount		Carrying		Balance		Discount		Carrying
							Amount						Amount
	1.25% Cash Convertible Senior Notes		$	345,000	$	69,873	$	275,127	$	345,000	$	77,529	$	267,471
	Senior Secured Credit Facilities (long-term portion)			289,054		1,662		287,392		280,000		2,338		277,662
	Senior Secured Credit Facilities (current portion)			25,313		915		24,398		16,875		982		15,893
	Total debt		$	659,367	$	72,450	$	586,917	$	641,875	$	80,849	$	561,026
Interest Expense	'
	Interest expense consisted of the following:
			Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)		2014		2013		2014		2013
	Interest expense		$	4,190	$	3,653	$	12,074	$	10,918
	Amortization of discounts			2,842		2,732		8,400		3,055
	Amortization of debt issuance costs			510		510		1,531		3,157
	Write off of unamortized deferred debt issuance costs			0		0		0		3,901
	Total interest expense		$	7,542	$	6,895	$	22,005	$	21,031
Interest Expense Related to Notes	'
	Interest expense related to the 1.25% Notes was comprised of the following:
			Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)		2014		2013		2014		2013
	Coupon interest at 1.25%		$	1,078	$	1,078	$	3,234	$	1,234
	Amortization of original issuance discount			2,598		2,474		7,656		2,797
	Amortization of debt issuance costs			295		295		885		344
	Total interest expense related to the 1.25% Notes		$	3,971	$	3,847	$	11,775	$	4,375
Summary of Future Payment Obligations under Notes and Senior Secured Credit Facilities	'
	The following table summarizes our future principal payment obligations under the 1.25% Notes and the senior secured credit facility as of September 30, 2014:
	(In thousands)		Total		Remainder of		2015		2016		2017		2018		Thereafter
					2014
	1.25% Cash Convertible Senior Notes (1)		$	345,000	$	0	$	0	$	0	$	0	$	0	$	345,000
	Senior Secured Term Loan		$	208,125		5,625		28,125		39,375		50,625		84,375		0
	Senior Secured Revolving Facility		$	106,242		0		0		0		0		106,242		0
			$	659,367	$	5,625	$	28,125	$	39,375	$	50,625	$	190,617	$	345,000
	-1	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Income_Taxes_Tables

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Effective Tax Rates	'
	The effective tax rates were as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(Dollar amounts in thousands)	2014			2013			2014			2013
	Loss before income taxes	($	26,211	)	($	51,173	)	($	61,480	)	($	113,564	)
	Income tax benefit (provision)	$	448		$	2,233		($	2,795	)	$	30,156
	Effective tax rate		1.7	%		4.4	%		(4.5	%)		26.6	%

Derivative_Financial_Instrumen1

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Activity Related to Interest Rate Swap Agreement	'
	We recognized the following activity related to our interest rate swap agreement:
		Three Months Ended September 30,						Nine Months Ended September 30,
	(In thousands)	2014			2013			2014			2013
	Effective portion
	Current period increase in fair value recognized in other comprehensive (loss) income, net	$	110		$	207		$	427		$	856
	Tax effect		(43	)		(82	)		(168	)		(334	)
	Net	$	67		$	125		$	259		$	522
	Loss reclassified from accumulated other comprehensive loss to interest expense	$	110		$	286		$	465		$	968
	Amount excluded from effectiveness assessment and ineffective gain (loss) recognized in other income (expense), net	$	0		$	0		$	0		$	0

Business_Segments_Tables

Business Segments (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts	'
		Three Months Ended September 30,						Nine Months Ended September 30,
	(In thousands)	2014			2013			2014			2013
	Revenue:
	Clinical and Financial Solutions	$	207,207		$	208,554		$	627,075		$	647,035
	Population Health		71,828			64,006			211,922			189,889
	Managed Services		63,674			53,230			188,586			166,388
	Unallocated Amounts		2,680			4,401			9,387			18,772
	Total revenue	$	345,389		$	330,191		$	1,036,970		$	1,022,084
	Gross Profit:
	Clinical and Financial Solutions	$	99,241		$	95,867		$	299,998		$	302,432
	Population Health		46,975			45,728			143,548			126,069
	Managed Services		1,048			4,161			12,861			16,437
	Unallocated Amounts		(15,808	)		(20,209	)		(46,777	)		(48,681	)
	Total gross profit	$	131,456		$	125,547		$	409,630		$	396,257
	Income (Loss) from operations:
	Clinical and Financial Solutions	$	47,987		$	34,980		$	139,107		$	121,545
	Population Health		26,950			30,240			77,349			74,824
	Managed Services		1,048			4,161			12,861			16,437
	Unallocated Amounts		(94,825	)		(112,833	)		(269,161	)		(312,862	)
	Total loss from operations	($	18,840	)	($	43,452	)	($	39,844	)	($	100,056	)

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	Sep. 30, 2014
In Millions, unless otherwise specified
Accounting Policies [Abstract]	'
Unrecognized tax benefit presented as a reduction to deferred tax asset	$4

Business_Combinations_Addition

Business Combinations - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Mar. 31, 2014

Mar. 04, 2013

Sep. 30, 2014

Sep. 30, 2013

Jul. 08, 2014

Sep. 30, 2014

Jul. 08, 2014

Sep. 30, 2014

Oasis Technology and Trade Name Intangible Assets [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

dbMotion [Member]

Jardogs [Member]

Jardogs [Member]

Jardogs [Member]

Oasis Medical Solutions Limited [Member]

Oasis Medical Solutions Limited [Member]

Oasis Medical Solutions Limited [Member]

Oasis Medical Solutions Limited [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Selling, General and Administrative Expenses [Member]

Cost of revenue [Member]

Cost of revenue [Member]

Cost of revenue [Member]

Cost of revenue [Member]

Cost of revenue [Member]

Cost of revenue [Member]

Cost of revenue [Member]

Cost of revenue [Member]

Cost of revenue [Member]

Cost of revenue [Member]

Purchase Price Allocation Adjustment [Member]

Oasis Customer Relationships [Member]

Acquisition-related Costs [Member]

Acquisition-related Costs [Member]

Acquisition-related Costs [Member]

Acquisition-related Costs [Member]

Acquisition-related Costs [Member]

Professional Services [Member]

Professional Services [Member]

Professional Services [Member]

Professional Services [Member]

System Sales [Member]

System Sales [Member]

Maintenance [Member]

Maintenance [Member]

Employee Compensation Costs [Member]

Employee Compensation Costs [Member]

Employee Compensation Costs [Member]

Employee Compensation Costs [Member]

Seller Transaction Costs [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Date of acquisition

'

'

'

'

'

'

'

'

4-Mar-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4-Mar-13

'

'

8-Jul-14

'

'

Aggregate consideration with a fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$24,000,000

'

'

$20,600,000

'

'

'

Acquired cash and cash equivalents, and restricted cash

'

'

'

'

'

'

'

'

14,188,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

Assets acquired ,accounts receivable and other current assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,700,000

'

Assets acquired , intangible assets related to technology

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,300,000

'

Assets acquired, intangible assets related to customer relationships

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,500,000

'

Assets acquired, goodwill

1,200,651,000

'

1,200,651,000

'

1,189,585,000

'

'

'

137,649,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,600,000

'

Assets acquired, fixed assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

Liabilities assumed, accounts payable, deferred revenue and accruals

'

'

'

'

'

'

'

'

10,560,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,400,000

'

Liabilities assumed, deferred tax liabilities net

'

'

'

'

'

'

'

'

36,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,700,000

'

Amortization period of acquired intangible assets excluding goodwill

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'12 years

Increase in fair value of the consideration transferred

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase in goodwill

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000,000

'

'

'

'

'

'

'

Acquisition-related costs

'

'

'

'

'

'

'

'

'

'

800,000

1,800,000

3,600,000

6,000,000

800,000

1,800,000

3,600,000

4,200,000

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

700,000

'

'

'

'

Product consolidation activities

188,000

7,371,000

2,134,000

10,504,000

'

'

'

2,400,000

'

5,500,000

'

2,400,000

'

5,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization of software development costs and acquisition-related assets

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,900,000

$4,700,000

($100,000)

$1,100,000

($400,000)

$1,200,000

$1,000,000

$1,700,000

$800,000

$1,800,000

'

'

'

'

'

'

'

'

Final_Fair_Value_of_Considerat

Final Fair Value of Consideration Transferred for Acquisition (Detail) (dbMotion [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Business Acquisition [Line Items]	'
Cash	$140,079
Allscripts common stock, 3,823,453 shares, par value $0.01 per share, fair value at closing $12.57 per share	48,061
Fair value of Allscripts' previous interest in dbMotion	8,367
Total fair value of consideration transferred	226,178
Deferred Cash Consideration [Member]	'
Business Acquisition [Line Items]	'
Liabilities incurred on total consideration transferred	23,023
Subordinated Promissory Note [Member]	'
Business Acquisition [Line Items]	'
Liabilities incurred on total consideration transferred	$6,648

Final_Fair_Value_of_Considerat1

Final Fair Value of Consideration Transferred for Acquisition (Parenthetical) (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014
			dbMotion [Member]	dbMotion [Member]	dbMotion [Member]
				Deferred Cash Consideration [Member]	Subordinated Promissory Note [Member]
Business Acquisition [Line Items]	'	'	'	'	'
Common stock, shares	264,914	263,474	3,823,453	'	'
Common stock, par value	$0.01	$0.01	$0.01	'	'
Common stock, fair value	'	'	$12.57	'	'
Period of acquisition liability incurred	'	'	'	'18 months	'18 months

Assets_Acquired_and_Liabilitie

Assets Acquired and Liabilities Assumed (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Business Acquisition [Line Items]	'	'
Goodwill	$1,200,651	$1,189,585
dbMotion [Member]	'	'
Business Acquisition [Line Items]	'	'
Acquired cash and cash equivalents, and restricted cash	14,188	'
Accounts receivable, net	3,226	'
Prepaid expenses and other current assets	574	'
Fixed assets and other long-term assets	1,449	'
Goodwill	137,649	'
Intangible assets	85,450	'
Accounts payable and accrued liabilities	-10,560	'
Deferred taxes, net	-36	'
Deferred revenue	-5,100	'
Other liabilities	-662	'
Net assets acquired	$226,178	'

Proforma_Results_Detail

Proforma Results (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
dbMotion [Member]	'	'
Business Acquisition [Line Items]	'	'
Revenue	$124	$852
Net loss	-9,579	-21,119
Combined Entity [Member]	'	'
Business Acquisition [Line Items]	'	'
Revenue	331,527	1,025,951
Net loss	($47,139)	($86,667)
Net loss per share, basic and diluted	($0.26)	($0.49)

Summary_of_Financial_Assets_an

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total	$476	$3,524
Interest rate swap [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	-31	-458
1.25% Call Option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other assets	67,677	104,656
Money market funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0	3,634
Marketable securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Long-term marketable securities	1,321	1,329
Cash conversion option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	-68,491	-105,637
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total	0	3,634
Level 1 [Member] | Interest rate swap [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	0	0
Level 1 [Member] | 1.25% Call Option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other assets	0	0
Level 1 [Member] | Money market funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0	3,634
Level 1 [Member] | Marketable securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Long-term marketable securities	0	0
Level 1 [Member] | Cash conversion option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	0	0
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total	1,290	871
Level 2 [Member] | Interest rate swap [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	-31	-458
Level 2 [Member] | 1.25% Call Option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other assets	0	0
Level 2 [Member] | Money market funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0	0
Level 2 [Member] | Marketable securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Long-term marketable securities	1,321	1,329
Level 2 [Member] | Cash conversion option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	0	0
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total	-814	-981
Level 3 [Member] | Interest rate swap [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	0	0
Level 3 [Member] | 1.25% Call Option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other assets	67,677	104,656
Level 3 [Member] | Money market funds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents	0	0
Level 3 [Member] | Marketable securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Long-term marketable securities	0	0
Level 3 [Member] | Cash conversion option [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Other liabilities	($68,491)	($105,637)

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (USD $)	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014
In Millions, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Total consideration for non marketable equity securities	$15.10	$15.10	$6
Value of equity investment	'	'	4.1
Value of commercial agreement	'	'	1.9
Carrying value of cost method investment	17.8	'	'
Carrying value of equity method investment	$1.40	'	'
1.25% Cash Convertible Senior Notes [Member]	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'
Interest rate	1.25%	'	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Apr. 30, 2011	Sep. 30, 2014	Sep. 30, 2013	Jun. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Capital Unit [Line Items]	'	'	'	'	'	'	'
Stock options granted	'	0	200,000	'	0	3,800,000	'
Capitalized stock-based compensation costs	'	$0	$0	'	$0	$0	'
Share issued, exercise of options and release of stock awards	'	'	'	'	1,400,000	'	2,600,000
Common stock repurchased, shares	'	'	'	0	'	'	0
Stock repurchase program, expiring date	9-May-14	'	'	'	'	'	'
Shares settled for tax withholding	'	'	'	'	549,000	564,000	'
Warrant [Member] | Commercial partner [Member]	'	'	'	'	'	'	'
Capital Unit [Line Items]	'	'	'	'	'	'	'
Number of warrants issued	'	1,500,000	'	'	1,500,000	'	'
Initial exercise price of warrant per share	'	$12.94	'	'	$12.94	'	'
Number of installments	'	'	'	'	4	'	'
Number of warrants vested during period	'	375,000	'	'	375,000	'	'
Warrant expiration period	'	'	'	'	'2020-06	'	'
Fair value recognized as reduction to transaction processing and other revenue	'	$600,000	$800,000	'	$1,900,000	$800,000	'

Weighted_Average_Grant_Date_Fa

Weighted Average Grant Date Fair Value Information and Related Valuation Assumptions (Detail) (USD $)	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Weighed-average exercise price	$15.22	$13.78
Expected term (in years)	'4 years 9 months	'4 years 9 months
Expected volatility	48.00%	54.90%
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	1.40%	0.80%

StockBased_Compensation_Expens

Stock-Based Compensation Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock based compensation expense	$10,055	$9,678	$32,203	$27,788
Cost of revenue [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock based compensation expense	1,335	1,292	4,720	4,311
Cost of revenue [Member] | Professional Services [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock based compensation expense	622	607	2,086	1,924
Cost of revenue [Member] | Maintenance [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock based compensation expense	285	313	1,084	1,116
Cost of revenue [Member] | Transaction processing and other [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock based compensation expense	428	372	1,550	1,271
Selling, General and Administrative Expenses [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock based compensation expense	7,881	6,606	20,999	17,418
Research and development [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock based compensation expense	$839	$1,780	$6,484	$6,059

StockBased_Awards_Granted_Deta

Stock-Based Awards Granted (Detail) (USD $)	3 Months Ended	9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares, granted	13	2,141
Weighted-Average Grant Date Fair Value, granted	$14.91	$17.79
Service-Based Restricted Stock Units [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares, granted	13	1,453
Weighted-Average Grant Date Fair Value, granted	$14.91	$18.09
Performance-Based Restricted Stock Units with a Service Condition [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares, granted	0	467
Weighted-Average Grant Date Fair Value, granted	$0	$18.51
Market-Based Restricted Stock Units with a Service Condition [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares, granted	0	221
Weighted-Average Grant Date Fair Value, granted	$0	$14.36

Calculations_of_Earnings_Loss_

Calculations of Earnings (Loss) Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Net loss	($25,763)	($48,940)	($64,275)	($83,408)
Net loss available to common stockholders	-25,763	-48,940	-64,275	-83,408
Weighted-average common shares outstanding	180,189	178,166	179,691	176,517
Basic Loss per Common Share	($0.15)	($0.27)	($0.36)	($0.47)
Net loss	-25,763	-48,940	-64,275	-83,408
Net loss available to common stockholders	($25,763)	($48,940)	($64,275)	($83,408)
Weighted-average common shares outstanding	180,189	178,166	179,691	176,517
Dilutive effect of stock options, restricted stock unit awards and warrants	0	0	0	0
Weighted-average common shares outstanding assuming dilution	180,189	178,166	179,691	176,517
Diluted Loss per Common Share	($0.15)	($0.27)	($0.36)	($0.47)

AntiDilutive_Stock_Options_Res

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted (Loss) Earnings Per Share (Detail)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	24,117	24,839	24,314	11,388

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$1,002,215	$988,165
Accumulated Amortization	-632,023	-584,194
Intangible Assets, Net	370,192	403,971
Registered trademarks	52,000	52,000
Goodwill	1,200,651	1,189,585
Total	1,252,651	1,241,585
Proprietary Technology [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Gross Carrying Amount	451,320	445,960
Accumulated Amortization	-258,511	-231,634
Intangible Assets, Net	192,809	214,326
Customer Contracts and Relationships [Member]	'	'
Schedule Of Goodwill And Intangible Assets [Line Items]	'	'
Gross Carrying Amount	550,895	542,205
Accumulated Amortization	-373,512	-352,560
Intangible Assets, Net	$177,383	$189,645

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Additional goodwill recognized	$10,600,000	$1,000,000	$11,568,000	'
Accumulated impairment losses associated with goodwill	$0	'	$0	$0

Changes_in_Carrying_Amount_of_

Changes in Carrying Amount of Goodwill (Detail) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2014

Mar. 31, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Jul. 08, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Oasis Medical Solutions Limited [Member]

Oasis Medical Solutions Limited [Member]

dbMotion [Member]

Clinical and Financial Solutions [Member]

Clinical and Financial Solutions [Member]

Clinical and Financial Solutions [Member]

Population Health [Member]

Population Health [Member]

Population Health [Member]

Managed Services [Member]

Managed Services [Member]

Managed Services [Member]

Oasis Medical Solutions Limited [Member]

dbMotion [Member]

Oasis Medical Solutions Limited [Member]

dbMotion [Member]

Oasis Medical Solutions Limited [Member]

dbMotion [Member]

Schedule Of Goodwill And Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill

$1,189,585

'

$1,189,585

'

'

'

'

$625,769

'

'

$425,216

'

'

$138,600

'

'

Additions arising from business acquisitions

10,600

1,000

11,568

'

10,568

'

1,018

10,568

10,568

0

1,018

0

1,018

0

0

0

Foreign exchange translation

'

'

-520

'

'

'

'

-520

'

'

0

'

'

0

'

'

Impairment of goodwill

'

'

0

'

'

'

'

0

'

'

0

'

'

0

'

'

Goodwill, net

$1,200,651

'

$1,200,651

$1,189,585

'

$10,600

$137,649

$635,817

'

'

$426,234

'

'

$138,600

'

'

Asset_Impairment_Charges_Addit

Asset Impairment Charges - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Asset Impairment Charges [Line Items]	'	'	'	'
Non-cash charges recorded to earnings	$188	$7,371	$2,134	$10,504
MyWay [Member]	'	'	'	'
Asset Impairment Charges [Line Items]	'	'	'	'
Non-cash charges recorded to earnings	200	5,000	700	5,000
Capitalized Software Development Projects [Member]	'	'	'	'
Asset Impairment Charges [Line Items]	'	'	'	'
Non-cash charges recorded to earnings	'	'	1,400	'
dbMotion [Member]	'	'	'	'
Asset Impairment Charges [Line Items]	'	'	'	'
Non-cash charges recorded to earnings	'	$2,400	'	$5,500

Asset_Impairment_Charges_Detai

Asset Impairment Charges (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Asset Impairment Charges [Abstract]	'	'	'	'
Asset impairment charges	$188	$7,371	$2,134	$10,504

Debt_Outstanding_Excluding_Cap

Debt Outstanding Excluding Capital Lease Obligations (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Principal Balance	$659,367	$641,875
Unamortized Discount	72,450	80,849
Net Carrying Amount	586,917	561,026
1.25% Cash Convertible Senior Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal Balance	345,000	345,000
Unamortized Discount	69,873	77,529
Net Carrying Amount	275,127	267,471
Senior Secured Credit Facilities (long-term portion) [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal Balance	289,054	280,000
Unamortized Discount	1,662	2,338
Net Carrying Amount	287,392	277,662
Senior Secured Credit Facilities (current portion) [Member]	'	'
Debt Instrument [Line Items]	'	'
Principal Balance	25,313	16,875
Unamortized Discount	915	982
Net Carrying Amount	$24,398	$15,893

Interest_Expense_Detail

Interest Expense (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Debt Disclosure [Abstract]	'	'	'	'
Interest expense	$4,190	$3,653	$12,074	$10,918
Amortization of discounts	2,842	2,732	8,400	3,055
Amortization of debt issuance costs	510	510	1,531	3,157
Write off of unamortized deferred debt issuance costs	0	0	0	3,901
Total interest expense	$7,542	$6,895	$22,005	$21,031

Interest_Expense_Related_to_No

Interest Expense Related to Notes (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Debt Instrument [Line Items]	'	'	'	'
Coupon interest at 1.25%	$4,190	$3,653	$12,074	$10,918
Amortization of original issuance discount	2,842	2,732	8,400	3,055
Amortization of debt issuance costs	510	510	1,531	3,157
Total interest expense	7,542	6,895	22,005	21,031
1.25% Cash Convertible Senior Notes [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Coupon interest at 1.25%	1,078	1,078	3,234	1,234
Amortization of original issuance discount	2,598	2,474	7,656	2,797
Amortization of debt issuance costs	295	295	885	344
Total interest expense	$3,971	$3,847	$11,775	$4,375

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Debt Instrument [Line Items]	'
Letters of credit outstanding	$0.90
Senior secured credit facility interest rate spread	2.75%
Unamortized deferred debt issuance costs	10
Senior Secured Term Loan [Member]	'
Debt Instrument [Line Items]	'
Interest rate	2.90%
Borrowings outstanding in term loan	208.1
Senior Secured Revolving Facility [Member]	'
Debt Instrument [Line Items]	'
Interest rate	2.90%
Credit facility, amount borrowed	106.3
Credit facility, amount available	$317.30
1.25% Cash Convertible Senior Notes [Member]	'
Debt Instrument [Line Items]	'
Interest rate	1.25%

Summary_of_Future_Payment_Obli

Summary of Future Payment Obligations under Notes and Senior Secured Credit Facilities (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Total	$659,367	$641,875
Remainder of 2014	5,625	'
2015	28,125	'
2016	39,375	'
2017	50,625	'
2018	190,617	'
Thereafter	345,000	'
1.25% Cash Convertible Senior Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	345,000	345,000
Remainder of 2014	0	'
2015	0	'
2016	0	'
2017	0	'
2018	0	'
Thereafter	345,000	'
Senior Secured Term Loan [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	208,125	'
Remainder of 2014	5,625	'
2015	28,125	'
2016	39,375	'
2017	50,625	'
2018	84,375	'
Thereafter	0	'
Senior Secured Revolving Facility [Member]	'	'
Debt Instrument [Line Items]	'	'
Total	106,242	'
Remainder of 2014	0	'
2015	0	'
2016	0	'
2017	0	'
2018	106,242	'
Thereafter	$0	'

Summary_of_Future_Payment_Obli1

Summary of Future Payment Obligations under Notes and Senior Secured Credit Facilities (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
1.25% notes maturity period	1-Jul-20

Effective_Tax_Rates_Detail

Effective Tax Rates (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Loss before income taxes	($26,211)	($51,173)	($61,480)	($113,564)
Income tax benefit (provision)	$448	$2,233	($2,795)	$30,156
Effective tax rate	1.70%	4.40%	-4.50%	26.60%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'	'
Valuation Allowance	$6.30	$24.10	'
Cumulative operating income loss period considered	'	'3 years	'
Unrecognized income tax benefits	$15.40	$15.40	$18.30

Derivative_Financial_Instrumen2

Derivative Financial Instruments - Additional Information (Detail) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Jun. 18, 2013

Oct. 29, 2010

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

1.25% Notes Embedded Cash Conversion Options [Member]

1.25% Notes Embedded Cash Conversion Options [Member]

1.25% Notes Embedded Cash Conversion Options [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Interest rate swap [Member]

Interest rate swap [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

Level 3 [Member]

Level 3 [Member]

Short [Member]

Short [Member]

Short [Member]

Short [Member]

Short [Member]

Short [Member]

Short [Member]

Short [Member]

1.25% Call Option [Member]

1.25% Call Option [Member]

1.25% Notes Embedded Cash Conversion Options [Member]

1.25% Notes Embedded Cash Conversion Options [Member]

1.25% Notes Embedded Cash Conversion Options [Member]

1.25% Notes Embedded Cash Conversion Options [Member]

Fair Value Measurements [Member]

Fair Value Measurements [Member]

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of option

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$67,700,000

$104,700,000

Gain (Loss) on call options

'

'

'

'

'

'

'

'

'

-35,400,000

21,400,000

-37,000,000

19,700,000

35,600,000

-22,300,000

37,200,000

-20,600,000

'

'

Fair value liability of embedded cash conversion option

68,400,000

105,600,000

82,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate swap agreement effective date

'

'

'

29-Oct-10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional amount of interest rate swap agreement

'

'

'

300,000,000

50,000,000

'

50,000,000

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate swap agreement termination date

'

'

'

31-Oct-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective fixed interest rate for swap agreement

'

'

'

'

0.90%

'

0.90%

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of interest rate swap agreement

'

'

'

'

0

'

0

'

500,000

'

'

'

'

'

'

'

'

'

'

Gains (losses) reclassified from OCI into earnings due to forecasted transactions that failed to occur

'

'

'

'

$0

$0

$0

$0

'

'

'

'

'

'

'

'

'

'

'

Activity_Related_to_Interest_R

Activity Related to Interest Rate Swap Agreement (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'	'	'	'
Current period increase in fair value recognized in other comprehensive (loss) income, net	$110	$207	$427	$856
Tax effect	-43	-82	-168	-334
Unrealized gain on interest rate swap, net of tax	67	125	259	522
Loss reclassified from accumulated other comprehensive loss to interest expense	110	286	465	968
Amount excluded from effectiveness assessment and ineffective gain (loss) recognized in other income (expense), net	$0	$0	$0	$0

Contingencies_Additional_Infor

Contingencies - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended	0 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Feb. 26, 2013
		Cardinal Health 200, LLC [Member]	Cardinal Health 200, LLC [Member]
			Minimum [Member]
Loss Contingencies [Line Items]	'	'	'
Damages in connection with claims related to breach of contract	'	'	$3,978,000
Expected trial date scheduled	'	'2015-06	'
Amount paid in connection with resolution of claims	$9,800,000	'	'

Business_Segments_Additional_I

Business Segments - Additional Information (Detail)	1 Months Ended		9 Months Ended
	Sep. 30, 2014	Nov. 30, 2013	Sep. 30, 2014
	Segment	Segment	Segment
Segment Reporting [Abstract]	'	'	'
Number of reportable segments	3	5	'
Number of operating segments	'	'	9

Revenues_and_Income_from_Opera

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	$345,389	$330,191	$1,036,970	$1,022,084
Gross Profit	131,456	125,547	409,630	396,257
Income (Loss) from operations	-18,840	-43,452	-39,844	-100,056
Unallocated Amounts [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	2,680	4,401	9,387	18,772
Gross Profit	-15,808	-20,209	-46,777	-48,681
Income (Loss) from operations	-94,825	-112,833	-269,161	-312,862
Clinical and Financial Solutions [Member] | Operating Segments [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	207,207	208,554	627,075	647,035
Gross Profit	99,241	95,867	299,998	302,432
Income (Loss) from operations	47,987	34,980	139,107	121,545
Population Health [Member] | Operating Segments [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	71,828	64,006	211,922	189,889
Gross Profit	46,975	45,728	143,548	126,069
Income (Loss) from operations	26,950	30,240	77,349	74,824
Managed Services [Member] | Operating Segments [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue	63,674	53,230	188,586	166,388
Gross Profit	1,048	4,161	12,861	16,437
Income (Loss) from operations	$1,048	$4,161	$12,861	$16,437

North_American_Site_Consolidat1

North American Site Consolidation Plan - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Feb. 18, 2013
						Office
						Warehouse
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Research and development	$45,962,000	$49,400,000	$151,283,000	$151,881,000	'	'
North American Site Consolidation Plan [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Number of offices closed under the Site Consolidation Plan	'	'	'	'	'	12
Number of Warehouse closed under the Site Consolidation Plan	'	'	'	'	'	1
Severance costs (benefits)	-100,000	3,400,000	-2,200,000	17,200,000	'	'
Research and development	'	1,900,000	'	2,600,000	'	'
Payments of severance costs	'	'	2,000,000	'	'	'
Accrued severance costs	$0	$11,200,000	$0	$11,200,000	$4,200,000	'